Evidence map›Paper›PMID 33414556›Full record

ReviewNature chemical biology2021

Harnessing nanotechnology to expand the toolbox of chemical biology.

Ryan M Williams, Shi Chen, Rachel E Langenbacher, Thomas V Galassi, Jackson D Harvey, Prakrit V Jena, Januka Budhathoki-Uprety, Minkui Luo, Daniel A Heller

Abstract readReview
In one paragraph

Review in Nature chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  5. Article
  6. Advances of medical nanorobots for future cancer treatments.Journal of hematology & oncology · 2023
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryan M Williams *Department of Biomedical Engineering, The City College of New York, New York, NY, USA.ORCID http://orcid.org/0000-0002-2381-8732
Shi Chen *Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachel E LangenbacherMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thomas V GalassiMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jackson D HarveyMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Prakrit V JenaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Januka Budhathoki-UpretyDepartment of Textile Engineering, Chemistry and Science, North Carolina State University, Raleigh, NC, USA. jbudhat@ncsu.edu.ORCID http://orcid.org/0000-0003-3395-4823
Minkui LuoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. luom@mskcc.org.ORCID http://orcid.org/0000-0001-7409-7034
Daniel A HellerMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hellerd@mskcc.org.ORCID http://orcid.org/0000-0002-6866-0000

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Interrogating Protein Methyltransferases with Integrated ApproachesR35GM131858 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI Minkui Luo · 2019 to 2026
$6.3M
Profile substrates and inhibitors of protein lysine methyltransferaseR01GM096056 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2011 to 2018
$3.2M
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor MicroenvironmentR01CA215719 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2018 to 2022
$3.1M
Tumor-Selective Delivery Approaches for MedulloblastomaR01NS116353 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, RAJU, PRAVEEN B. · 2020 to 2024
$3.1M
Transient Metabolite Detection for Single-Cell Metabolomics and DiagnosticsDP2HD075698 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2012 to 2012
$2.7M
Mechanisms of Cell Communication in Animal DevelopmentR35GM124878 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI ROY, SOUGATA · 2017 to 2021
$2.1M
Interrogating Functions of Protein Methyltransferases with Chemical ToolsR01GM120570 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2016 to 2019
$1.8M
Renal tubule-specific nanotherapeutics for acute kidney injuryR01DK114321 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, JAIMES, EDGAR A · 2018 to 2020
$796k
NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215719NICHD NIH HHS DP2 HD075698NIDDK NIH HHS R01 DK114321NIGMS NIH HHS R01 GM096056NIGMS NIH HHS R01 GM120570NIGMS NIH HHS R35 GM124878NIGMS NIH HHS R35 GM131858NINDS NIH HHS R01 NS116353
6 · The paper itself

Abstract

Although nanotechnology often addresses biomedical needs, nanoscale tools can also facilitate broad biological discovery. Nanoscale delivery, imaging, biosensing, and bioreactor technologies may address unmet questions at the interface between chemistry and biology. Currently, many chemical biologists do not include nanomaterials in their toolbox, and few investigators develop nanomaterials in the context of chemical tools to answer biological questions. We reason that the two fields are ripe with opportunity for greater synergy. Nanotechnologies can expand the utility of chemical tools in the hands of chemical biologists, for example, through controlled delivery of reactive and/or toxic compounds or signal-binding events of small molecules in living systems. Conversely, chemical biologists can work with nanotechnologists to address challenging biological questions that are inaccessible to both communities. This Perspective aims to introduce the chemical biology community to nanotechnologies that may expand their methodologies while inspiring nanotechnologists to address questions relevant to chemical biology.

Indexed as

AnimalsBiocompatible MaterialsDrug CarriersDrug Delivery SystemsEnzymesHumansMolecular BiologyMolecular ImagingNanoparticlesNanotechnologyBiocompatible MaterialsDrug CarriersEnzymes

Identifiers

PMID33414556
PMCPMC8288144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.